Deanxit Research Articles

Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression.

The aim of this study is to explore paroxetine's effect on nerve growth factor (NGF), human neurotrophin-4 (NT-4), and brain-derived neurotrophic factor (BDNF) levels in post-stroke depression. Ninety-two post-stroke depression patients from April 2021 to April 2023 in our hospital were selected and numbered 1 to 92 after enrollment. Forty-six patients with odd number and 46 patients with even number were, respectively, included in the control and observation group. In addition to basic treatment, control group was treated with flupentixol melitracen tablets orally, and observation group received paroxetine hydrochloride orally. The levels of NGF, NT-4, BDNF, 5-hydroxytryptamine (5-HT), homocysteine (Hcy), noradrenaline (NE), Hamilton Depression Scale (HAMD) changes of National Institute of Health Stroke Scale (NIHSS). NGF, NT-4, and BDNF levels were compared between groups at T0, T1, and T2 levels were higher, and the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); NGF, NT-4, and BDNF levels were compared among groups, time, and interaction. 5-HT, Hcy, and NE levels at T0 were compared between groups; 5-HT and NE levels at T1 and T2 were higher than those at T0, the levels at T2 were higher than those at T1, and observation group levels were higher (P < 0.05); Hcy level at T1 and T2 was lower, its level at T2 was lower than those at T1, and observation group levels were lower (P < 0.05); 5-HT, Hcy, and NE levels were compared among groups, time, and interaction (P < 0.05). HAMD and NIHSS at T0 were compared; T1 and T2 were lower than T0, T2 was lower than T1, and observation group was lower (P < 0.05); HAMD and NIHSS were compared among groups, time, and interaction (P < 0.05). For post-stroke depression, paroxetine treatment can effectively improve NGF, NT-4, BDNF, 5-HT, Hcy, and NE levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value.

Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial.

Long-course (LC) antidepressants for the treatment of disorders of gut-brain interaction, such as refractory functional dyspepsia (rFD), pose patients at risk of antidepressant discontinuation syndrome (ADS). Short-course (SC) therapy of rapid-acting antidepressant may reduce discontinuation syndromes while maintaining efficacy for dyspeptic symptoms. However, the evidence-based research is lacking. This study aims to determine whether SC therapy with antidepressants could decrease the risk of ADS with comparable treatment efficacy to LC therapy in rFD. This randomized clinical trial with rFD patients was conducted at a tertiary hospital in China. Participants (N = 240) were randomly allocated to receive flupentixol-melitracen (FM) plus omeprazole therapy for 2 (SC group) or 4 (LC group) weeks, respectively. Scores for Leeds Dyspepsia Questionnaire (LDQ), Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 for Depression (PHQ-9) were assessed at baseline and every 2 weeks, ending at 4 weeks after treatment. ADS was assessed after drug cessation. Medication possession ratio (MPR) for FM was calculated. The severity and incidence of ADS of patients in SC group were significantly lower than those in LC group (0.60 ± 0.62 vs. 1.71 ± 1.58 and 3.64 vs. 39.45%; both P < 0.0001). The MPR values for FM were significantly higher in patients of SC group than in LC group (P < 0.0001). Scores for LDQ, GAD-7 and PHQ-9 decreased in patients of both groups, and the symptom improvement in SC group was comparable to that in LC group after treatment. Compared to 4-week FM therapy, the 2-week FM therapy reduces the risk of ADS with non-inferior treatment efficacy in patients with rFD. Clinical trials.gov, identifier NCT05099913.

Tanshinone IIA ameliorates chronic unpredictable mild stress-induced depression-like behavior and cognitive impairment in rats through the BDNF/TrkB/GAT1 signaling pathway

BackgroundDepression is a common disorder with a complex pathogenesis. Tanshinone IIA (TAN IIA) is a botanical agent with neuroprotective and antidepressant properties. ObjectiveTo examine the effects of TAN IIA on chronic unpredictable mild stress (CUMS)-induced depression-like behavior and cognitive impairment in rats. MethodsRats were exposed to CUMS for 4 weeks, followed by the oral administration of TAN IIA, Deanxit (DEAN), or normal saline for an additional 4 weeks. The control rats were fed with regular chow and administered with normal saline for 4 weeks. Behavioral tests were performed to assess the effects of TAN IIA on depression-like behavior and cognitive impairment in rats with CUMS. The morphology of dendrites was analyzed by Golgi staining. Immunofluorescence staining was performed to determine protein localization. ResultsTAN IIA treatment ameliorated CUMS-induced depression-like behavior and cognitive impairment in rats. TAN IIA treatment also reversed the effects of CUMS on dendritic complexity and the levels of gamma-aminobutyric acid (GABA) in the hippocampus and prefrontal cortex. Rats with CUMS showed decreased levels of brain-derived neurotrophic factor (BDNF) and phosphorylated tropomyosin receptor kinase B (TrkB), upregulated expression of GABA transporter 1 (GAT1), and reduced expression of synaptic proteins in the hippocampus, while TAN IIA treatment significantly diminished the effects of CUMS exposure. In addition, GAT1 was colocalized with N-methyl-D-aspartate receptor 2B. ConclusionTAN IIA ameliorates CUMS-induced depression-like behavior and cognitive impairment in rats by regulating the BDNF/TrkB/GAT1 signaling pathway, suggesting that TAN IIA may be a candidate drug for the treatment of depression.

Chinese Herbal Medicine for Functional Dyspepsia With Psychological Disorders: A Systematic Review and Meta-Analysis

Background and AimsFunctional dyspepsia (FD) is closely associated with gut–brain interaction disorder (DGBI), characterized by the interaction of gastrointestinal symptoms and central nervous system dysregulation. Chinese herbal medicine (CHM) has a good concurrent effect in the treatment of FD, especially for patients with concurrent psychological disorders. A meta-analysis was designed to evaluate the efficacy and safety of CHMs in the treatment of FD.MethodsThe PubMed, Embase, Cochrane Library, Web of Science, Chinese Biological Medical Database (CBM), Wanfang Data, China National Knowledge Infrastructure (CNKI), and China Science and Technology Journal Database (VIP) were searched to collect randomized controlled trials of FD treated with CHM. The retrieval time limit is from the establishment of the database till 11 April 2022. Two researchers independently searched databases, screened documents, extracted data, and evaluated the risk of bias of included studies. RevMan 5.4 software was used for meta-analysis.ResultsA total of 11 studies including 951 patients were included. The study was divided into two parts. The first part included 5 clinical trials, including 471 patients. The experimental group was treated only with CHM and the control group was only treated with placebo. The results of first part showed that the total effective rate of CHM in the treatment of FD was higher than that in the placebo group (84.5 vs. 49.4%) [relative risk (RR) = 1.76; 95% confidence interval (CI) (1.13, 2.75); P = 0.01]. In addition, CHM treatment could reduce the total symptom score [standardized mean difference (SMD) = −10.05; 95% CI (−13.50, −6.59); Z = 5.70; P < 0.0001] and depression score [SMD = −7.68; 95% CI (−14.43, −0.94); Z = 2.23; P = 0.03]. The second part included 6 clinical trials, including 480 patients. The experimental group was only treated with CHM and the control group was treated with prokinetic agents combined with flupentixol melitracen (deanxit). The results of second part showed that the total effective rate of CHM in the treatment of FD was higher than that of the control group (92.6 vs. 78.8%) [RR = 1.17; 95% CI (1.09, 1.26), P < 0.0001]. In addition, CHM treatment could reduce HAMA score [mean difference (MD) = −3.19; 95% CI (−3.79, −2.59); Z = 10.40; P < 0.00001], HAMD score [MD = −4.32; 95% CI (−6.04, −2.61); Z = 4.94; P < 0.00001], and gastric emptying rate [MD = 12.62; 95% CI (5.84, 19.40); Z = 3.65; P = 0.0003]. The results of the two parts of the meta-analysis showed no serious adverse reactions, and there was no significant difference in the adverse reactions between the experimental group and the control group [MD = 1.14; 95% CI (0.53, 2.42); Z = 0.33; P = 0.74]; [MD = 0.14; 95% CI (0.01, 2.67); Z = 1.30; P = 0.19].ConclusionThe current evidence shows that CHM treatment has great potential and safety in alleviating the symptoms of FD and improving the psychological disorders of anxiety and depression in patients with FD. Limited by the quantity and quality of the included studies and other biases, the above conclusions need more high-quality studies to be verified.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier [CRD42022311129].

Comparative Efficacy of Antidepressants for Symptoms Remission of Gastroesophageal Reflux: A Bayesian Network Meta-analysis of Randomized Controlled Trials.

The present study aimed to compare and evaluate the efficacy of antidepressants in remission of esophageal reflux symptoms. A comprehensive literature review was performed including sources published on MEDLINE, EMBASE, the Cochrane Central Registry of Controlled Trials (Cochrane), Web of Science, China National Knowledge Infrastructure Database (CNKI), Chinese VIP Information Databases (VIP), Chinese Biology Medicine disc (CBM), and Wan-Fang databases for randomized controlled trials, published up to and including March 31, 2020. We analyzed relevant randomized, placebo-controlled trials reporting the effect of antidepressant therapy in relieving esophageal reflux symptoms ADDIS 1.16.8 was used to perform the network meta-analysis. Furthermore, we performed a split analysis to test inconsistency, and rank probability was complemented for comparison among antidepressants. A total of 10 randomized controlled trials (RCTs) examining the effects of antidepressants, selective 5-HT reabsorption inhibitor (SSRI), 5-HT 1A receptor agonist (5-HT1AA), tricyclic antidepressants (TCAs), and the complex of flupentixol-melitracen (FM) were included. Flupentixol-melitracen and SSRIs exhibited a significantly higher rate of remission than placebo. However, there was no statistically significant difference among different antidepressants compared. Rank probability showed that FM exhibited the highest probability of rank 1 compared with other antidepressants and placebo. This network meta-analysis of RCTs supported the use of FM and SSRIs as a potentially effective regimen for symptom remission of gastroesophageal reflux. Furthermore, according to our analysis, FM represents the most efficient antidepressant with highest probability of symptom remission.

Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database

BackgroundPsychotropic medications are useful to treat psychiatric disorders which are frequently underdiagnosed and undertreated in cancer patients. Evidence on utilisation of psychotropic medications in cancer patients was absent in China. This study aimed to analyse the prevalence and the potential predictors of psychotropic medication use in adult cancer patients in China. MethodsWe analysed cross-sectional data from the China Health Insurance Association database in 2015–2017, which contained health care utilisation information for a national representative sample of basic medical insurance beneficiaries. Cancer patients aged above 18 were identified by International Classification of Disease 10th revision code C00–C97. Psychotropic medications were defined following the Anatomical Therapeutic Chemical codes: antipsychotics (N05A), anxiolytics (N05B), hypnotics and sedatives (N05C), and antidepressants (N06A, N06CA). We calculated the prevalence of psychotropic medication use in cancer patients, and applied multivariable logistic regression to identify its potential predictors. FindingsA total of 260,364 adults with cancer were identified in the database, of which 48,111 (18•5%) were prescribed at least one psychotropic medication comprising antipsychotics (3763, 1•4%), anxiolytics (15,902, 6•1%), hypnotics and sedatives (37,040, 14•2%), and antidepressants (2379, 0•9%). Patients with solid tumours had higher prevalence of psychotropic medication use than patients with lymphoid and hematopoietic malignancies (e.g. female genital organs, adjusted odds ratio (OR)=2•25, 95%CI=2•09–2•44). The prevalence of psychotropic medication use in cancer patients in the Eastern region was significantly higher than those of cancer patients in the Western regions (OR=2•33, 95%CI=2•27–2•40). Compared with the Urban Rural Resident Basic Medical Insurance beneficiaries, cancer patients covered by the Urban Employee Basic Medical Insurance were more likely to use psychotropic medications (OR=1•18, 95%CI=1•15–1•20). Midazolam was the most frequently used psychotropic (21,728, 45•2%), and flupentixol–melitracen was the most commonly used antidepressant (1176, 2•4%) among all psychotropic medication users in the sample. InterpretationThe prevalence of psychotropic medication use in Chinese adult cancer patients was inequitable. Further attention will be needed to be paid to the mental health of cancer patients in China. FundingNo funding.

Effect of anti-allergic drug combined with deanxit on emotional symptoms and quality of life in elderly patients with allergic rhinitis

Sixty-three elderly patients with allergic rhinitis and symptoms of anxiety and depression attending in the Affiliated Hospital of Yangzhou University from August 2016 to August 2018 were randomly divided into two groups: 30 patients received deanxit combined with anti-allergic drugs for treatment (study group) and another 30 patients received anti-allergic drugs treatment alone (control group). Subjective nasal obstruction was evaluated by Visual Analogue Scale (VAS), and the quality of life of patients was assessed by Rhinoconjunetivitis Quality of Life Questionnaire (RQLQ).The anxiety and depression mood changes were assessed by Self-rating Anxiety Scale (SAS) sand Self-rating Depression Scale (SDS).The scores of symptoms and mood were compared after 4 weeks and 8 weeks of treatment. The clinical nasal symptoms VAS score, the total RQLQ scores and its 7 domains scores, SDS and SAS scores of patients in two groups were significantly reduced compared to those before treatment (P<0.05). The VAS score, the total of RQLQ scores and its 7 domains scores, SDS and SAS scores were significantly lower in the study group than those in the control group after 4 weeks and 8 weeks of treatment.The total effective rate of study group was significantly higher than those of the control group (χ2=6.922, P=0.031; χ2=11.544, P=0.003). Deanxit combined with anti-allergic drugs shows significant clinical efficacy, it also can improve the symptoms of anxiety and depression, and the quality of life for elderly patients with allergic rhinitis. Key words: Rhinitis, allergic; Aged; Quality of life; Depression; Anxiety

A preliminary study of resting-state fMRI in patients with diarrhea-type irritable bowel syndrome after pinaverium bromide combined treatment with flupentixol-melitracen

Objective: To observe the difference of brain activity in patients with diarrhea-type irritable bowel syndrome (IBS-D) treated with pinaverium bromide (PB) combined with flupentixol-melitracen (FM), and to explore the mechanism of efficacy of combined with anxiolytic/antidepressant drugs in IBS-D patients at the central level, using resting-state functional magnetic resonance imaging (rs-fMRI). Methods: Forty-eight patients with IBS-D, including 28 males, 20 females, mean age 22-48 (33±7) years, were selected from the Affiliated Hospital of Hangzhou Normal University from October 2015 to October 2018.All patients with IBS-D underwent rs-fMRI scans before and after receiving either PB (basic treatment group, n=16), PB combined with FM (combination therapy group, n=16), or no medication (no treatment group, n=16). Rs-fMRI regional homogeneity (ReHo) parameter among the three groups of patients were compared using One-way ANOVA analysis and post analysis.Partial correlation and mediation analyses were performed on ReHo values and the improvement of symptoms scores (gastrointestinal symptom rating scale(GSRS) and hospital anxiety/depression scale (HAD)) in the two medicated groups. Results: No significant differences in ReHo values were observed among the three groups before treatment. Compared with patients on no-medication, patients receiving either PB or PB-FM showed decreased ReHo in the striatum, insular lobe, medial prefrontal cortex (MPFC) and subcallosal gyrus, and increased ReHo in the occipital cortex. In particular, the combined treatment group showed more extensive decreased ReHo in the left thalamus and left temporal pole, and increased in the left precuneus. Compared with the basic treatment group, the combined treatment group showed decreased ReHo in the right putamen, right insula, right MPFC and subcallosal gyrus, and increased ReHo in the left precuneus. In addition, the combined treatment group demonstrated a positive correlation between ReHo values in the left thalamus and the improvement of HAD score (r=0.653, P=0.011) , and a negative correlation between ReHo values in left precuneus and the improvement of GSRS and HAD score (r=-0.771, P=0.001; r=-0.716, P=0.004). ReHo values in the left precuneus were observed to mediate between gastrointestinal symptoms and anxiety-depressive symptoms in the combined treatment group. Conclusions: The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS. In addition to more extensive changes in pain-related brain areas, IBS-D patients treated with anxiolytic/antidepressant also show changes in default network and brain areas related to emotional regulation, and are associated with improvement in gastrointestinal symptoms, anxiety and depression.

PS1510 FLUPENTIXOL MELITRACEN COMBINED WITH ONDANSETRON IN PREVENTION OF NAUSEA AND VOMITING INDUCED BY CONDITIONING IN PATIENT TO UNDERGO HSCT

Background:Nausea and vomiting are the most common complaints for patients with haematological neoplasia during conditioning. The risk of hematopoiesis stem cell transplantation (HSCT) always cause people in anxiety and depression, which add patients’ discomforts.Aims:The aim of this study is to observe the effect of lupentixol melitracen combined with ondansetron on nausea and vomiting.Methods:160 patients with hematological neoplasia in the state of complete remission were included in this study. The patients were randomly divided into control group and lupentixol melitracen group. For patients in control group, they received recommended‐dose of ondansetron during conditioning each day. For patients in lupentixol melitracen group, they received lupentixol melitracen 10.5 mg combined with ondansetron each day. The incidence of nausea and vomiting was evaluated before, during and after chemotherapeutics infusion in the first day of conditioning.Results:Totally 158 patients, 78 in control group and 80 in lupentixol melitracen group could be evaluated. The difference of chemotherapy drug intensity in the two groups has no statistical significance (P &gt; 0.05). The incidence of nausea before, during and immediately after chemotherapeutics infusion was respectively 5.2%, 72.5%, 60.6% in the control group and 1.6%, 53.3%, 45.5% in the lupentixol melitracen group, and the difference was significant between the two groups (P &lt; 0.05). While the incidence of vomiting in the two groups has no significant difference (P &gt; 0.05).Summary/Conclusion:Flupentixol melitracen combined with ondansetron is more effective to prevent nausea than single ondansetron in patients during the first day of conditioning but no more effect on vomiting in our study.

Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.

Background:There are many trials on the combination of Pinaverium bromide (PB) and Flupentixol-melitracen (FM) in the treatment of diarrhea-type irritable bowel syndrome (IBS-D), but the sample sizes are small, and the research conclusions are inconsistent. Thus, a meta-analysis was performed, aiming to evaluate the efficacy and safety of this combination therapy in patients with IBS-D.Methods:A systematic literature search was conducted in 7 databases covering the period up to July 2018 to identify randomized controlled trials (RCTs) of PB combined with FM versus PB alone for IBS-D. The primary outcome was the total symptom relief rate. The other outcomes were the adverse events rate, HAMA/SAS score, and HAMD/SDS score. The methodological quality of the RCTs was assessed independently using 6 criteria according to the Cochrane Collaboration. All data were analyzed using Review Manager 5.3.Results:Fifteen RCTs with 1487 participants were identified from 2005 to 2018. Compared with PB alone, 15 RCTs showed significant effects of PB plus FM in terms of improved symptom relief in patients with IBS-D (n = 1487, OR = 5.17, 95%CI, 3.79–7.07, P < .00001). Eleven RCTs reported adverse effects in both the PB plus FM and PB groups, there was no statistically significant difference in the adverse events rate between the 2 groups (n = 1207, OR = 2.91, 95%CI, 0.91–9.28, P = 0.07). Two RCTs and 3 RCTs reported HAMA and HAMD scores respectively, and 3 RCTs reported both SAS and SDS scores. After treatment, the above scores in the PB plus FM group were significantly lower than the PB group (all P < .01). However, the trials were deemed to have a medium risk of bias.Conclusions:The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use. However, the conclusions still need to be verified by conducting more large-scale and high-quality RCTs.

Clinical effect of Zhizhukuanzhong capsule combined with Deanxit in the treatment of functional dyspepsia of spleen-deficiency and qi-stagnation

Objective To investigate the curative effect of Zhizhukuanzhong capsule combined with Deanxit in the treatment of functional dyspepsia(FD) of spleen-deficiency and qi-stagnation. Methods Seventy-six patients with FD were randomly divided into three groups.A group (24 cases)_was given Zhizhukuanzhong combined with Deanxit, B group (26 cases) was given Zhizhukuanzhong, C group (26 cases) received trimebutine dispersible tablets treatment.After treatment for 8 weeks, the symptoms of indigestion, depressive state and therapeutic effect were observed. Results Before treatment, there were no statistically significant differences in the symptoms of dyspepsia(all P>0.05). After treatment, the symptoms of dyspepsia were improved in different degree, the effective rates of A, B, C three groups were 91.6%, 65.4% and 42.3%, respectively, there was no statistically significant difference between A group and B group(χ2=1.579, P=0.209); there was statistically significant difference between A group and C group(χ2=13.549, P=0.000); there was no statistically significant difference between B group and C group(χ2=2.786, P=0.09). The FD patients complicated with varying degrees of anxiety and depression, there was no statistically significant difference among the three groups before treatment(P>0.05). After treatment, comparison of HAMA and HAMD scores among the three groups: there were statistically significant differences between A group and B group (tHAMA=6.839, tHAMD=4.607, all P 0.05). The adverse reactions of A group were mainly weakness, dizziness, drowsiness, which were alleviated within 2 weeks.The adverse reactions of B group were slight stomach disease and stool frequency increased, which not affected the treatment.The adverse reactions of C group were digestive tract symptoms, which lasted for more than 2 weeks. Conclusion Zhizhukuanzhong capsule combined with Deanxit in the treatment of FD of spleen-deficiency and qi-stagnation can obtain good curative effect, it is safe, convenient, and with minor side effects, good compliance. Key words: Dyspepsia; Flupenthixol; Medicine, Chinese traditional

Effect of lansoprazole combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety

Objective To observe the clinical effect of lansoprazole enteric-coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety. Methods Eighty patients with erosive gastritis complicated with anxiety were selected, and they were randomly divided into control group(n=40) and observation group(n=40) according to the digital table.The control group was treated with lansoprazole enteric-coated tablets.The observation group received lansoprazole enteric-coated tablets combined with flupentixol and melitracen.Hamming anxiety scale(HAMA) and Hamilton depression scale(HAMD) were used to evaluate in the two groups before and after treatment.The changes of HAMA and HAMD scores were compared between the two groups. Results Before treatment, the scores of abdominal pain, bloating, pantothenic acid and belching had no statistically significant differences between the two groups (all P>0.05). After treatment for 4 weeks, the scores of abdominal pain, bloating, pantothenic acid and belching in the observation group were (0.63±0.12)points, (0.43±0.11)points, (0.30±0.11)points and (0.31±0.14)points, respectively, which were lower than those in the control group [(1.42±0.18)points, (1.08±0.15)points, (0.79±0.16)points, (0.98±0.25)points] (t=15.396, 13.285, 16.758, 17.492, all P 0.05). Conclusion Lansoprazole enteric-coated tablets combined with flupentixol and melitracen in the treatment of erosive gastritis with anxiety can relieve anxiety and depression, improve clinical symptoms and treatment effect. Key words: Lansoprazole; Flupentixol melitracen; Gastritis; Anxiety

Observation of Flupentixol and melitracen on curative effect of sudden deafness patients with anxiety and depression in different stages

Objective:To investigate the efficacy of flupentixol melitracen on different stages of sudden deafness patients with anxiety and depression.Method:Totally one hundred and sixty-three sudden deafness patients with anxiety and depression were randomly divided into two groups: experimental group(81 cases) and control group (82 cases). All patients were given routine treatment for 2 weeks. The experimental group was given oral flupentixol melitracen (1 tablet/day)for a period of 3 months. The hearing, tinnitus effect and vertigo treatment course were observed and compared. Curing rate of tinnitus at 2 weeks, 3 months and 6 months after treatment, self-rating anxiety scale (SAS) and depressive state scale (self-rating depression scale, SDS) score were collected and compared.Result:Total efficiency of hearing and tinnitus of experimental group(86.42%,84.21%)were higher than that of the control group(67.07%,61.29%);the vertigo cured the average treatment time of experimental group days was less than that of the control groupdays,all the differences were statistically significant.After treatment,the average hearing threshold value of the two groups of patients were lower than that before treatment,the low frequency descent type, high-frequency descent type,flat down type and total deafness type thresholds of the experimental group were lower than of the control group,all the differences were statistically significant.The tinnitus cure rate of experiment group were higher than the control group at 3months and 6 months after treatment,the differences were statistically significant;and after 3months and 6 months treatment tinnitus cure rate higher of the experimental group than that of after 2 weeks the treatment,the difference was statistically significant.After 2 weeks,3 months and 6 months treatment,the SAS and SDS scores of two groups were lower than that before treatment.The SAS and SDS scores of the experimental group decreased after 2 weeks,3 months and 6 months treatment, and the difference was statistically significant at different time points,the SAS,SDS scores of experimental group after treatment were lower than the control group at the same time,the differences were statistically significant.Conclusion:For the sudden deafness patients with anxiety and depression , the combination of flupentixol melitracen on the basis of conventional therapy can improve the clinical efficacy, the patient's mental status and long-term therapeutic effect of tinnitus..

Observation of the clinical curative effect of flupentixol/melitracen combined with mosapride citrate in the treatment of functional dyspepsia

Objective To investigate the clinical curative effect of flupentixol/melitracen(deanxit) combined with mosapride citrate in the treatment of functional dyspepsia. Methods The clinical data of 240 patients with functional dyspepsia were collected, According to different treatment method, they were divided into two groups, 120 patients of the control group were treated with mosapride citrate combined with omeprazole, 120 patients of the observation group were treated with deanxit combined with mosapride citrate.One course of treatment was 4 weeks.After one course of treatment, the clinical curative effects and adverse reactions of the two groups were evaluated. Results After treatment, the abdominal distension, abdominal pain, early satiety, belching and other symptoms scores of the two groups were significantly lower compared with before treatment, the differences were statistically significant(all P 0.05). Conclusion Deanxit combined with mosapride citrate in the treatment of functional dyspepsia is one of the important method, and its clinical effect is satisfactory, relatively safe, it is worthy of popularization and application. Key words: Dyspepsia; Flupentixol/melitracen; Mosapride

Evaluation of anti anxiety treatment in residual dizziness after successful canalith repositioning procedure in benign paroxysmal positional vertigo

Objective To study the effect of anti anxiety treatment in residual dizziness after successful canalith repositioning procedure in benign paroxysmal positional vertigo. Methods 68 cases of benign paroxysmal position vertigo patients with residual dizziness after successful canalith repositioning procedure were collected, who visit department of Neurology..They were randomly assigned to anti anxiety group and the control group according to randomized controlled method.Deanxit (0.5mg/10mg, 1times/day) combined with betahistine mesilate tablets (6mg, 3 times/day) were taken by patients in the anti anxiety group; take betahistine mesilate tablets (6mg, 3 times/day) were taken in the control group.Follow up 3 months, the duration of residual dizziness and the changes of symptoms between the two groups were compared.The symptoms of all patients were evaluated before and after treatment by dizziness handicap inventory. Results The duration of residual dizziness in the control group was (16.38±8.83)days, and that in the anti anxiety group was (10.13±5.10)days.The duration of residual dizziness in the anti anxiety group was significantly shorter than that in the control group (t=3.440, P 0.05) in the treatment of first week.In second week and third week, the scores of the anti anxiety group were lower than those of the control group, the differences were statistically significant (t=3.378, 4.935, all P<0.05). After 3 weeks of treatment, the scores of the anti anxiety group were significantly decreased in the functional, emotional and physical scores (t=5.297, 4.537, 4.451, all P<0.01). Conclusion Deanxit can shorten residual dizziness duration of benign paroxysmal position vertigo patients after successful canalith repositioning procedure, and can reduce the degree of residual dizziness. Key words: Vertigo; Otolithic membrane; Deanxit

The clinical efficacy of fluoride faction shouted tons melitracen sheet for functional gastrointestinal disorders with abdominal pain symptoms

Objective To study and analyze the effect of fluoride faction shouted tons melitracen sheet (Deanxit) on abdominal pain symptoms of functional gastrointestinal disorders (FGIDs). Methods 82 patients with abdominal pain FGIDs were randomly divided into A group(n=40) and B group(n=42). A group was given conventional treatment, group B was given deanxit treatment on the basis of A group.The treatment efficacy and the total incidence of adverse reactions were analyzed. Results The total effective rate of group B (90.24%) was significantly higher than that in group A (65.85%), the difference was statistically significant (χ2=4.538, P 0.05). Conclusion Deanxit in the treatment of FGIDs can achieve satisfactory therapeutic effect, the drug can significantly alleviate the symptoms, andit is safe and without serious side effects. Key words: Functional gastrointestinal disorders; Fluoride faction shouted tons melitracen; Abdominal pain; Clinical efficacy

Supplemented Ganmai-Dazao decoction for malignant tumor-related depression: comparsion with flupentixol and melitracen tablets

Objective To evaluate the curative effect of supplemented Ganmai-Dazao decoction for malignant tumor correlation with depression. Methods A total of 98 patients with malignant tumor-related depression were divided into a treatment group and a control group according to the random number table. The control group were treated with flupentixol and melitracen tablets (Deanxit) combined with conventional treatment, the treatment group were treated with oral administration of traditional Chinese medicine supplemented Ganmai-Dazao decoction combined with conventional treatment for 8 weeks. The Hamilton Depression Scale (HAMD) was used to evaluate the curative effect. Results The effective rate showed no significant difference between the treatment group and the control group (79.59% vs. 75.51%; χ2=0.059, P=0.809). HAMD scores in both groups were significantly decreased after the treatment than before treatment (12.8 ± 3.4 vs. 29.4 ± 4.7 in the treatment group, 12.3 ± 3.6 vs. 28.7 ± 4.5 in the control group, all P<0.05), there was no significant difference in HAMD scores after the treatment between the treatment group and the control group (t=0.707, P=0.481). Conclusion Curative effect of supplemented Ganmai-Dazao decoction is equal to flupentixol and melitracen tablets in patients with malignant tumor-related depression. Key words: Neoplasms; Depression; Antidepressive agents; Drugs, Chinese herbal; Gan Mai Da Zao Tang

Clinical efficacy of Deanxit in non-erosive gastroesophageal reflux disease with anxiety and depression

Objective To investigate clinical effects of Deanxit in non-erosive gastroesophageal reflux disease (NERD) with anxiety and depression. Methods A total of 76 patients diagnosed NERD with anxiety and depression by endoscopy and hospital anxiety and depression scale (HAD) were randomly divided into regular treatment group and Deanxit treatment group. Clinical efficacy, symptom score, and anxiety and depression score were observed after one week, four weeks, and eight weeks. Results Deanxit significantly increased the clinical efficacy after one week (P<0.01) and remission rate after one week (P<0.05), four and eight weeks (P<0.01). It improved symptoms, depression, and anxiety, which showed significant differences (P<0.01) compared to control group after one week, four and eight weeks administration. Conclusions Deanxit can be applied in NERD with anxiety and depression treatment, which has quick effect and high remission rate, and improve patient's reflux symptoms and anxiety depression. Key words: Flupenthixol/TU; Gastroesophageal reflux/CO/DT; Anxiety; Depression

Effects of anti-somatisation therapy on the quality of life in patients with functional dyspepsia

Objective To explore somatic symptoms of patients with functional dyspepsia (FD) and effects of combined anti somatisation therapy on the quality of life in patients with FD.Methods Two hundred and nineteen patients with FD were enrolled.Patient Health Questionnaire-15 (PHQ-15) and Nepean Dyspepsia Index (NDI) were completed,and the relation between them was analyzed.Lansoprazole,mosapride and flupentixol melitracen (the anti-somatisation medication) were taken for four weeks by 131 FD patients who had poor response to four-week conventional treatment with proton pump inhibitors (PPI) and/or prokinetic medication and who got more than 4 scores in PHQ 15.And then therapeutic effects were observed and the changes of NDI before and after treatment were analyzed.The t test,chi-square test,Spearman's correlation and linear regression were performed for statistical analysis.Results The total PHQ-15 and NDI score of 219 patients with FD were 5.7±3.4 and 42.0± 10.4,and there was positive correlation between them (r=0.493,P＜0.05).Stomach pain,headache,chest pain,dizziness,shortness of breath,fatigue,sleeping disorder,thirst and so on were positively correlated with totalNDIscore (r=0.262,0.230,0.241,0.243,0.352,0.385,0.266,0.281,all P＜0.05).Chest pain,stomach pain,shortness of breath,dizziness and fatigue were the influence factors of NDI (t=2.340,2.488,5.278,2.167,2.443,all P＜0.05).Among 131 patients with FD who received anti somatisation combination therapy,six patients did not complete the therapy because of the side effects,and finally 125 patients were enrolled and analyzed.Before and four weeks after the treatment,the total PHQ-15 scores of 125 patients with FD were 7.3±3.2 and 2.9±2.2,respectively; and the difference was statistically significant (t =12.653,P＜0.01).There were significant differences in the influence of stomach pain,headache,chest pain,dizziness,shortness of breath,fatigue,sleeping disorder and thirst before and after the treatment (not bothered at all,bothered a little,bothered a lot) (x2=39.231,6.796,6.693,15.520,6.698,51.572,44.390 and 16.506,all P＜0.05).The total NDI score before and after the treatment were 44.3 ± 11.7 and 29.2 ± 6.9,and the difference was statistically significant (t=12.503,P＜0.01).Conclusions The quality of life in patients with FD is affected by somatic symptoms such as chest pain,stomach pain,shortness of breath,dizziness,fatigue and so on.For FD patients with poor response to conventional treatment,the quality of life could be improved by the combination of anti-somatisation therapy and the conventional therapy. Key words: Dyspepsia; Somatisation; Quality of life; Treatment

Clinical outcomes of flupenthixol melitracen combined with conventional drugs on refractory asthma with anxiety and/or depression

Objective To investigate the clinical outcomes of flupenthixol melitracen on refractory asthma with anxiety and/or depression. Methods 105 patients with refractory asthma, who were given asthma controlled test (ACT) and comprehensive hospital anxiety and depression scale (HAD)test, were randomly classified into control group and treatment group, the former used recommended classical drugs in the consensus, Salmeterol Xinafoate and Fluticasone Propionate and Montelukast; while the latter used above therapy combining flupentixol melitrace. HAD score, ACT score and pulmonary function were applied to assess therapeutic effect. Results In 105 cases of refractory asthma patients, 75 patients were complicated with anxiety and/or depression, with prevalence of 71.42%. With the alleviation of anxiety and/or depression, the degree of asthma controlled was improved. After treatment, HAD score of the treatment group was lower that of control group((10.67±2.32)scores vs (11.94±3.02)scores, t=2.06, P<0.05), ACT score in treatment group was much higher than that of control group((14.54±3.14)scores vs (11.25±3.06)scores, t=4.59, P<0.01), there were statistical significance in FEV1%pre between two groups((55.29±5.72)vs (43.36±7.13), t=8.02, P<0.01). Conclusion Antidepressant treatment can alleviate anxiety and/or depression, improve the clinical curative effect of refractory asthma and help to improve lung function. Key words: Anxiety; Depression; Refractory asthma; Flupentixol Melitracen